Literature DB >> 21976659

Coagulation factor IX mediates serotype-specific binding of species A adenoviruses to host cells.

Annasara Lenman1, Steffen Müller, Mari I Nygren, Lars Frängsmyr, Thilo Stehle, Niklas Arnberg.   

Abstract

Human species A adenoviruses (HAdVs) comprise three serotypes: HAdV-12, -18, and -31. These viruses are common pathogens and cause systemic infections that usually involve the airways and/or intestine. In immunocompromised individuals, species A adenoviruses in general, and HAdV-31 in particular, cause life-threatening infections. By combining binding and infection experiments, we demonstrate that coagulation factor IX (FIX) efficiently enhances binding and infection by HAdV-18 and HAdV-31, but not by HAdV-12, in epithelial cells originating from the airways or intestine. This is markedly different from the mechanism for HAdV-5 and other human adenoviruses, which utilize coagulation factor X (FX) for infection of host cells. Surface plasmon resonance experiments revealed that the affinity of the HAdV-31 hexon-FIX interaction is higher than that of the HAdV-5 hexon-FX interaction and that the half-lives of these interactions are profoundly different. Moreover, both HAdV-31-FIX and HAdV-5-FX complexes bind to heparan sulfate-containing glycosaminoglycans (GAGs) on target cells, but binding studies utilizing cells expressing specific GAGs and GAG-cleaving enzymes revealed differences in GAG dependence and specificity between these two complexes. These findings add to our understanding of the intricate infection pathways used by human adenoviruses, and they may contribute to better design of HAdV-based vectors for gene and cancer therapy. Furthermore, the interaction between the HAdV-31 hexon and FIX may also serve as a target for antiviral treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21976659      PMCID: PMC3233144          DOI: 10.1128/JVI.06088-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  72 in total

Review 1.  Plasma exudation as a first line respiratory mucosal defence.

Authors:  C G Persson; I Erjefält; U Alkner; C Baumgarten; L Greiff; B Gustafsson; A Luts; U Pipkorn; F Sundler; C Svensson
Journal:  Clin Exp Allergy       Date:  1991-01       Impact factor: 5.018

2.  The human asialoglycoprotein receptor is a possible binding site for low-density lipoproteins and chylomicron remnants.

Authors:  E Windler; J Greeve; B Levkau; V Kolb-Bachofen; W Daerr; H Greten
Journal:  Biochem J       Date:  1991-05-15       Impact factor: 3.857

3.  Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer.

Authors:  Raul Alba; Angela C Bradshaw; Alan L Parker; David Bhella; Simon N Waddington; Stuart A Nicklin; Nico van Rooijen; Jerome Custers; Jaap Goudsmit; Dan H Barouch; John H McVey; Andrew H Baker
Journal:  Blood       Date:  2009-05-08       Impact factor: 22.113

4.  Structure of adenovirus type 21 knob in complex with CD46 reveals key differences in receptor contacts among species B adenoviruses.

Authors:  Karolina Cupelli; Steffen Müller; B David Persson; Marco Jost; Niklas Arnberg; Thilo Stehle
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

5.  Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5.

Authors:  J M Bergelson; J A Cunningham; G Droguett; E A Kurt-Jones; A Krithivas; J S Hong; M S Horwitz; R L Crowell; R W Finberg
Journal:  Science       Date:  1997-02-28       Impact factor: 47.728

6.  Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation.

Authors:  L V Rao; S I Rapaport
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

7.  Laboratory identification of adenoviruses associated with gastroenteritis in Canada from 1983 to 1986.

Authors:  M Brown
Journal:  J Clin Microbiol       Date:  1990-07       Impact factor: 5.948

8.  Genome type analysis of adenovirus 31, a potential causative agent of infants' enteritis.

Authors:  T Adrian; R Wigand
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

9.  "Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype.

Authors:  A Mastrangeli; B G Harvey; J Yao; G Wolff; I Kovesdi; R G Crystal; E Falck-Pedersen
Journal:  Hum Gene Ther       Date:  1996-01       Impact factor: 5.695

10.  Genome analysis of adenovirus type 31 strains from immunocompromised and immunocompetent patients.

Authors:  M E Johansson; M Brown; J C Hierholzer; A Thörner; H Ushijima; G Wadell
Journal:  J Infect Dis       Date:  1991-02       Impact factor: 5.226

View more
  12 in total

Review 1.  Interactions of viruses and the humoral innate immune response.

Authors:  Bailey E Maloney; Krishani Dinali Perera; Danielle R D Saunders; Naemi Shadipeni; Sherry D Fleming
Journal:  Clin Immunol       Date:  2020-02-04       Impact factor: 3.969

2.  Recombination of the epsilon determinant and corneal tropism: Human adenovirus species D types 15, 29, 56, and 69.

Authors:  Gurdeep Singh; Xiaohong Zhou; Jeong Yoon Lee; Mohammad A Yousuf; Mirja Ramke; Ashrafali M Ismail; Ji Sun Lee; Christopher M Robinson; Donald Seto; David W Dyer; Morris S Jones; Jaya Rajaiya; James Chodosh
Journal:  Virology       Date:  2015-09-07       Impact factor: 3.616

Review 3.  Humoral innate immune response and disease.

Authors:  Stephanie N Shishido; Sriram Varahan; Kai Yuan; Xiangdong Li; Sherry D Fleming
Journal:  Clin Immunol       Date:  2012-06-18       Impact factor: 3.969

4.  Human adenovirus 52 uses sialic acid-containing glycoproteins and the coxsackie and adenovirus receptor for binding to target cells.

Authors:  Annasara Lenman; A Manuel Liaci; Yan Liu; Carin Årdahl; Anandi Rajan; Emma Nilsson; Will Bradford; Lisa Kaeshammer; Morris S Jones; Lars Frängsmyr; Ten Feizi; Thilo Stehle; Niklas Arnberg
Journal:  PLoS Pathog       Date:  2015-02-12       Impact factor: 6.823

Review 5.  Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based Constructs.

Authors:  Julio Alonso-Padilla; Tibor Papp; Győző L Kaján; Mária Benkő; Menzo Havenga; Angelique Lemckert; Balázs Harrach; Andrew H Baker
Journal:  Mol Ther       Date:  2015-10-19       Impact factor: 11.454

6.  Defining a Novel Role for the Coxsackievirus and Adenovirus Receptor in Human Adenovirus Serotype 5 Transduction In Vitro in the Presence of Mouse Serum.

Authors:  Estrella Lopez-Gordo; Andor Doszpoly; Margaret R Duffy; Lynda Coughlan; Angela C Bradshaw; Katie M White; Laura Denby; Stuart A Nicklin; Andrew H Baker
Journal:  J Virol       Date:  2017-05-26       Impact factor: 5.103

7.  Polysialic acid is a cellular receptor for human adenovirus 52.

Authors:  Annasara Lenman; A Manuel Liaci; Yan Liu; Lars Frängsmyr; Martin Frank; Bärbel S Blaum; Wengang Chai; Iva I Podgorski; Balázs Harrach; Mária Benkő; Ten Feizi; Thilo Stehle; Niklas Arnberg
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-19       Impact factor: 11.205

8.  Early postmortem mapping of SARS-CoV-2 RNA in patients with COVID-19 and the correlation with tissue damage.

Authors:  Stefanie Deinhardt-Emmer; Daniel Wittschieber; Bettina Löffler; Gita Mall; Juliane Sanft; Sandra Kleemann; Stefan Elschner; Karoline Frieda Haupt; Vanessa Vau; Clio Häring; Jürgen Rödel; Andreas Henke; Christina Ehrhardt; Michael Bauer; Mike Philipp; Nikolaus Gaßler; Sandor Nietzsche
Journal:  Elife       Date:  2021-03-30       Impact factor: 8.140

Review 9.  Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome.

Authors:  Paolo Gresele; Stefania Momi; Rossella Marcucci; Francesco Ramundo; Valerio De Stefano; Armando Tripodi
Journal:  Haematologica       Date:  2021-12-01       Impact factor: 9.941

Review 10.  Human adenovirus binding to host cell receptors: a structural view.

Authors:  Aleksandra Cecylia Stasiak; Thilo Stehle
Journal:  Med Microbiol Immunol       Date:  2019-11-29       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.